Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug ravulizumab tested for kidney inflammation

NCT ID NCT04564339

Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tested the drug ravulizumab (Ultomiris) in 123 adults with lupus nephritis or IgA nephropathy, two conditions that cause kidney inflammation. Participants received either ravulizumab or a placebo alongside standard care. The study aimed to see if the drug could reduce protein in the urine, a sign of kidney damage. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ravulizumab (Ultomiris)
What this could lead to
If successful, this could point toward a new treatment option for kidney inflammation in lupus and IgA nephropathy.
What could go wrong
The trial was terminated early, so results are limited. It is a small Phase 2 study, and the drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

123 people

The number who actually took part.

Started

Jan 2021

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Common to both disease cohorts: * Proteinuria ≥1 (gram \[g\]/day or g/g) * Vaccinated against meningococcal infection * Vaccinated for Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae according to national/local regulatory requirements For LN cohort: * Diagnosis of active focal or diffuse proliferative LN Class III or IV * Clinically active LN, requiring/receiving immunosuppression induction treatment For IgAN cohort: * Diagnosis of primary IgAN * Compliance with stable and optimal dose of renin-angiotensin system inhibitor treatment for ≥ 3 months Exclusion Criteria: Common to both disease cohorts: * eGFR \< 30 milliliters/minute/1.73 meters squared * Previously received a complement inhibitor (for example, eculizumab) * Concomitant significant renal disease other than LN or IgAN * History of other solid organ or bone marrow transplant * Uncontrolled hypertension For IgAN cohort: * Diagnosis of rapid progressive glomerulonephritis * Prednisone or prednisone equivalent \> 20 milligram (mg) per day for \> 14 consecutive days or any other immunosuppression within 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immunoglobulin A nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glomerulonephritis IgA glomerulonephritis lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immunoglobulin A nephropathy Lupus nephritis

Contacts and locations

Locations

  • Research Site

    San Dimas, California, 91773, United States

  • Research Site

    Santa Monica, California, 90404, United States

  • Research Site

    South Gate, California, 90280, United States

  • Research Site

    Stanford, California, 94305, United States

  • Research Site

    Orlando, Florida, 32835, United States

  • Research Site

    Plantation, Florida, 33324, United States

  • Research Site

    Lawrenceville, Georgia, 30046, United States

  • Research Site

    Lexington, Kentucky, 40536, United States

  • Research Site

    Louisville, Kentucky, 40202, United States

  • Research Site

    Boston, Massachusetts, 02114, United States

  • Research Site

    Boston, Massachusetts, 02115, United States

  • Research Site

    Kansas City, Missouri, 64111, United States

  • Research Site

    New York, New York, 10003, United States

  • Research Site

    Chapel Hill, North Carolina, 27599, United States

  • Research Site

    Columbus, Ohio, 43203, United States

  • Research Site

    El Paso, Texas, 79935, United States

  • Research Site

    Houston, Texas, 77054, United States

  • Research Site

    Herston, 4029, Australia

  • Research Site

    Parkville, 3050, Australia

  • Research Site

    Westmead, 2145, Australia

  • Research Site

    London, Ontario, N6A 5W9, Canada

  • Research Site

    Montreal, Quebec, H1T 2M4, Canada

  • Research Site

    Québec, Quebec, G1R 2J6, Canada

  • Research Site

    Clermont-Ferrand, 63003, France

  • Research Site

    Le Kremlin-Bicêtre, 94270, France

  • Research Site

    Paris, 75020, France

  • Research Site

    Saint-Priest-en-Jarez, 42270, France

  • Research Site

    Strasbourg, 67091, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Berlin, 10117, Germany

  • Research Site

    Essen, 45147, Germany

  • Research Site

    Hanover, 30625, Germany

  • Research Site

    Lübeck, 23538, Germany

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Brescia, 25123, Italy

  • Research Site

    Florence, 50134, Italy

  • Research Site

    Torino, 10154, Italy

  • Research Site

    Maastricht, 6229 HX, Netherlands

  • Research Site

    Lodz, 92-213, Poland

  • Research Site

    Anyang-si, 14068, South Korea

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 134-727, South Korea

  • Research Site

    Seoul, 6591, South Korea

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Lleida, 25198, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28040, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Málaga, 29010, Spain

  • Research Site

    Palma de Mallorca, 07010, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Valencia, 46017, Spain

  • Research Site

    Zaragoza, 50009, Spain

  • Research Site

    Kaohsiung City, 80756, Taiwan

  • Research Site

    Kaohsiung City, 833401, Taiwan

  • Research Site

    New Taipei City, 23561, Taiwan

  • Research Site

    Taichung, 40447, Taiwan

  • Research Site

    Edgbaston, B15 2WB, United Kingdom

  • Research Site

    London, SE1 7EH, United Kingdom

  • Research Site

    London, W12 0HS, United Kingdom

  • Research Site

    Salford, M6 8HD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.